WO2001034642A3 - Control of neisserial membrane synthesis - Google Patents

Control of neisserial membrane synthesis Download PDF

Info

Publication number
WO2001034642A3
WO2001034642A3 PCT/US2000/031082 US0031082W WO0134642A3 WO 2001034642 A3 WO2001034642 A3 WO 2001034642A3 US 0031082 W US0031082 W US 0031082W WO 0134642 A3 WO0134642 A3 WO 0134642A3
Authority
WO
WIPO (PCT)
Prior art keywords
disclosed
methods
mutant
neisseria
control
Prior art date
Application number
PCT/US2000/031082
Other languages
French (fr)
Other versions
WO2001034642A2 (en
Inventor
Michael Apicella
Andrew Preston
Original Assignee
Univ Iowa Res Found
Michael Apicella
Andrew Preston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/439,226 external-priority patent/US6518037B2/en
Application filed by Univ Iowa Res Found, Michael Apicella, Andrew Preston filed Critical Univ Iowa Res Found
Priority to AU19175/01A priority Critical patent/AU1917501A/en
Publication of WO2001034642A2 publication Critical patent/WO2001034642A2/en
Publication of WO2001034642A3 publication Critical patent/WO2001034642A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/22—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Neisseriaceae (F), e.g. Acinetobacter

Abstract

The present invention discloses a mutant Neisseria having extensive membrane blebbing, both an indicium and a cause of virulence in the gonococcus and meningococcus. Methods are disclosed for making and characterizing the mutant, bmrRS. Methods are disclosed for isolating bmrRS membranes for use as a vaccine. Methods are also disclosed for identifying proteins that are unique to the mutant Neisseria. Proteins coded for or under the control of the bmr locus are provided. Methods are also disclosed for the use of the unique mutant proteins for determining the virulence of clinical samples of N. gonorrhoeae and N. meningitidis. Methods are also disclosed for the screening of antibiotics targeted to virulent Neisseria.
PCT/US2000/031082 1999-11-12 2000-11-13 Control of neisserial membrane synthesis WO2001034642A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU19175/01A AU1917501A (en) 1999-11-12 2000-11-13 Control of neisserial membrane synthesis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16521799P 1999-11-12 1999-11-12
US09/439,226 US6518037B2 (en) 1999-11-12 1999-11-12 Two-component system that controls bacterial membrane synthesis
US60/165,217 1999-11-12
US09/439,226 1999-11-12

Publications (2)

Publication Number Publication Date
WO2001034642A2 WO2001034642A2 (en) 2001-05-17
WO2001034642A3 true WO2001034642A3 (en) 2001-11-22

Family

ID=26861200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/031082 WO2001034642A2 (en) 1999-11-12 2000-11-13 Control of neisserial membrane synthesis

Country Status (2)

Country Link
AU (1) AU1917501A (en)
WO (1) WO2001034642A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5074644B2 (en) 1998-05-29 2012-11-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Combination meningococcal B / C vaccine
CA2373236C (en) 1999-05-19 2014-08-26 Chiron S.P.A. Combination neisserial compositions
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
EP2275129A3 (en) 2000-01-17 2013-11-06 Novartis Vaccines and Diagnostics S.r.l. Outer membrane vesicle (OMV) vaccine comprising N. meningitidis serogroup B outer membrane proteins
JP5511117B2 (en) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP4827726B2 (en) 2003-01-30 2011-11-30 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Injectable vaccine against multiple meningococcal serogroups
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
JP4993750B2 (en) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vesicular vaccine based on GNA1870 for broad protection against diseases caused by Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
ES2383231T3 (en) 2007-10-19 2012-06-19 Novartis Ag Formulations for meningococcal vaccines
ES2532946T3 (en) 2008-02-21 2015-04-06 Novartis Ag Meningococcal PUfH polypeptides
EP2265640B1 (en) 2008-03-10 2015-11-04 Children's Hospital & Research Center at Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
US8470340B2 (en) 2008-09-03 2013-06-25 Children's Hospital & Research Center Oakland Peptides presenting an epitope of a domain of factor H binding protein and methods of use
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
US9517263B2 (en) 2009-06-10 2016-12-13 Glaxosmithkline Biologicals Sa Benzonaphthyridine-containing vaccines
CN102596240B (en) 2009-08-27 2015-02-04 诺华股份有限公司 Hybrid polypeptides including meningococcal fHBP sequences
AU2010288239B2 (en) 2009-08-27 2014-01-16 Novartis Ag Adjuvant comprising aluminium, oligonucleotide and polycation
MX2012002723A (en) 2009-09-02 2012-04-11 Novartis Ag Immunogenic compositions including tlr activity modulators.
TWI445708B (en) 2009-09-02 2014-07-21 Irm Llc Compounds and compositions as tlr activity modulators
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
MX2012004850A (en) 2009-10-27 2012-05-22 Novartis Ag Modified meningococcal fhbp polypeptides.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
ES2631977T3 (en) 2009-12-15 2017-09-07 Glaxosmithkline Biologicals Sa Homogeneous suspension of immunopotentiating compounds and uses thereof
EP2547357A1 (en) 2010-03-18 2013-01-23 Novartis AG Adjuvanted vaccines for serogroup b meningococcus
KR101853513B1 (en) 2010-03-23 2018-04-30 노파르티스 아게 Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
BR122022015250B1 (en) 2010-03-30 2023-11-07 Children´S Hospital & Research Center At Oakland IMMUNOGENIC COMPOSITIONS AND THEIR USES
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
US20150147356A1 (en) 2011-05-12 2015-05-28 Alan Kimura Antipyretics to enhance tolerability of vesicle-based vaccines
JP2014529407A (en) 2011-08-31 2014-11-13 チルドレンズホスピタル アンド リサーチ センター オークランド Engineered sequences and methods of use for promoting antigen expression in Neisseria
EP2809785B1 (en) 2012-02-02 2017-11-01 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus
US10598666B2 (en) 2012-03-08 2020-03-24 Glaxosmithkline Biologicals Sa In vitro potency assay for protein-based meningococcal vaccines
CA2876138C (en) 2012-06-14 2023-09-19 Novartis Ag Vaccines for serogroup x meningococcus
CA2882619A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
EP3400960A1 (en) 2012-09-18 2018-11-14 GlaxoSmithKline Biologicals S.A. Outer membrane vesicles
BR112015018877A2 (en) 2013-02-07 2017-08-22 Externautics Spa METHOD FOR PREPARING A PHARMACEUTICAL COMPOSITION, AND IMMUNOGENIC PHARMACEUTICAL COMPOSITION
RS61246B1 (en) 2014-02-28 2021-01-29 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
NZ729206A (en) 2014-07-23 2022-07-01 Children’S Hospital & Res Center At Oakland Factor h binding protein variants and methods of use thereof
CA3035320A1 (en) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccines for neisseria gonorrhoeae
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059625A1 (en) * 1998-05-19 1999-11-25 University Of Maryland Vaccine delivery system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059625A1 (en) * 1998-05-19 1999-11-25 University Of Maryland Vaccine delivery system

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BULYGIN, V. V. ET AL.: "Rotation of the Epsilon Subunit during Catalysis by Escherichia coli FoFsub1-ATP Synthase", J. BIOL. CHEM., vol. 273, no. 48, 27 November 1998 (1998-11-27), pages 31765 - 31769, XP002167182 *
MEADOW, P. M. ET AL.: "The Effect of Lipopolysaccharide Composition on the Ultrastructure of Pseudomonas aeruginosa", J. GEN. MICROBIOL., vol. 105, 1978, pages 23 - 28, XP000990980 *
PETTIT, R. K. ET AL.: "Characterization of naturally elaborated blebs from serum-susceptible and serum-resistant strains of Neisseria gonorrhoeae", MOL. MICROBIOL., vol. 6, no. 6, 1992, pages 723 - 728, XP000990841 *
PRESTON, A. ET AL.: "A Two Component Regulatory System Involved in LOS Microheterogeneity in Neisseria gonorrhoeae", ABSTRACTS GRAL. MEET. ASM, vol. 96, 1996, pages 208, XP002167184 *
RAMÍREZ-ARCOS, S. ET AL.: "Expression and Interaction of the minCDE Genes of Neisseria gonorrhoeae", ABSTRACTS GRAL. MEET. ASM, vol. 99, June 1999 (1999-06-01), pages 352, XP002167181 *
SUZUKI, H. ET AL.: "Murein-Lipoprotein of Escherichia coli: A Protein Involved in the Stabilization of Bacterial Cell Envelope", MOL. GEN. GENET., vol. 167, 1978, pages 1 - 9, XP000990950 *
WATNICK, R. S. ET AL.: "Escherichia coli NusA is required for efficient RNA binding by phage HK022 Nun protein", PNAS, vol. 95, February 1998 (1998-02-01), pages 1546 - 1551, XP002167183 *
ZHOU D ET AL: "LIPOOLYGOSACHARIDE BIOSYNTHESIS IN NEISSERIA GONORRHOEAE: CLONING,IDENTIFICATION AND CHARACTERIZATION OF THE ALPHA1,5 HEPTOSYLTRANSFERASE 1 GENE (RFAC)", MOLECULAR MICROBIOLOGY,GB,BLACKWELL SCIENTIFIC, OXFORD, vol. 14, no. 4, 1994, pages 609 - 618, XP000770667, ISSN: 0950-382X *

Also Published As

Publication number Publication date
AU1917501A (en) 2001-06-06
WO2001034642A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2001034642A3 (en) Control of neisserial membrane synthesis
EP1900818A3 (en) Neisserial antigens
WO1998002547A3 (en) Dna and specific proteins or peptides of the neisseria meningitidis species bacteria, method for obtaining them and their biological applications
NZ515935A (en) Combination Neisserial compositions and vaccines for the prevention of infections due to Neisseria bacteria such as meningococcal meningitis
EP2270031A3 (en) Heterologous expression of neisserial proteins
EP1645631A3 (en) Neisseria antigens and compositions
EP1777233A3 (en) Gonococcal proteins and nucleic acids
CY1110540T1 (en) 85kDa ΑΝΤΙΓΟΝΟ NEISSERIAL
WO2000022430A3 (en) Neisseria genomic sequences and methods of their use
EP2275551A3 (en) Neisserial antigenic peptides
ATE427756T1 (en) NEISSERIA MENINGITIDIS SERUM GROUP B AND C ANTIGENS AND COMPOSITIONS CONTAINING AN ADDITIONAL ANTIGEN
EP2279746A3 (en) Surface proteins in neisseria meningitidis
EP2796148A3 (en) Combination meningitidis B/C vaccines
WO2000050074A3 (en) Neisserial vaccine compositions and methods
AU2003288558A1 (en) Meningococcal vaccine based on outer membrane proteins porb2 and pora
WO2004063222A3 (en) Novel preadipocyte factor-1-like polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase